The use of combination antiretroviral treatment of human immunodeficiency virus (HIV) has made AIDS a chronic controllable illness in many patients, and the incidence of opportunistic infections and the mortality have decreased considerably since early in the epidemic. The most common reason for ICU admission in patients with AIDS is respiratory failure, but they are less likely to be admitted for Pneumocystis pneumonia and other HIV-associated opportunistic infections. HIV-infected persons are more likely to receive ICU care for complications of end-stage liver disease and sepsis. Hepatitis C has emerged as a common cause of morbidity and mortality in patients with HIV infection. In addition, some develop life-threatening complications from antiretroviral drug toxicity, and the immune reconstitution inflammatory syndrome can lead to ICU admission.
W orldwide, more than 36 million people are estimated to be living with human immunodeficiency virus (HIV) or AIDS. More than 5 million become infected with HIV each year, and more than 3 million people died of AIDS in the year 2002. Once considered a uniformly fatal illness, the use of combination agents directed against HIV (highly active antiretroviral therapy, or HAART) has changed our concept of AIDS to a chronic controllable illness when HAART is used successfully. Since the introduction and prevalent use of HAART starting in 1996, the incidence of HIV-related opportunistic infections and mortality declined dramatically in the developed nations that have successfully used these drugs. 1, 2 Nevertheless, around 350,000 people are living with AIDS in the United States, and around 15,000 persons with AIDS die each year. In many urban communities, AIDS-related illnesses are still among the leading causes of death among young adults. 3 It still is not known if the benefits of HAART in reducing HIV-associated morbidity and mortality are reflected in reduced ICU admission, different diagnoses, or better outcomes for HIV-infected persons who develop lifethreatening illness. In the pre-HAART years, respiratory failure was the most common reason for ICU care, and it was usually due to Pneumocystis pneumonia (PCP). 4 Many people with HIV infection are treated in intensive care units for HIV-associated disorders other than PCP and for critical illness unrelated to HIV such as gastrointestinal hemorrhage, cardiovascular disease, sepsis, trauma, drug overdose, and disorders of the central nervous system. A few studies in the literature indicate that in the era of HAART, ICU admissions for PCP have declined, and overall outcomes seem to be improved. Patients may also become critically ill from the toxic effects of antiretroviral medications and from an accelerated inflammatory response related to immune reconstitution accompanying the use of HAART. This article summarizes what is known about the critical care of patients with HIV infection in the era of HAART.
Reasons for ICU Admission
The literature on the frequency and reasons for ICU admission in patients with HIV infection must be interpreted with the understanding that, with rare exception, these studies each relate the experience of single centers. Therefore, each center's conclusions reflect local ICU admission criteria and practice patterns and cannot be generalized to all units that treat HIV-infected patients. We know that ICU utilization and practices vary widely among different nations where economics play a large role in the selection of patients admitted to the ICU. Within the United States, ICU utilization and practice patterns for patients with AIDS vary widely among different centers. 5 The decision on whether to admit HIV-infected patients to the ICU or withhold such treatment varies by hospital characteristics (county/state, Veterans Affairs Medical Center, church affiliated, voluntary and for profit) and geographic location, and these differences are maintained after controlling for severity of illness and patient demographic and socioeconomic characteristics. Thus, data on diseases and outcomes from one center cannot be applied reliably to others.
In the pre-HAART years, an estimated 5% to 10% of hospitalizations of patients with HIV infection involved an ICU admission; most patients were admitted for respiratory failure, and PCP was the most common diagnosis. 6, 7 Before HAART, PCP was consistently the most common cause of respiratory failure, but it appears that ICU admissions for PCP have declined in recent years. 8 The few published studies of intensive care in the era of HAART suggest that overall ICU utilization by HIV-positive persons has not declined and that respiratory failure is still the most common reason for admission. However, patients are less likely to be admitted for PCP and other HIV-associated opportunistic infections. Rather, patients are now more likely to have life-threatening sepsis, neurologic disorders, and complications of end-stage liver disease. 9 -11 
Coinfection With Hepatitis C and HIV
With improved outcomes of HIV infection with HAART, hepatitis C virus (HCV) has emerged as a very common cause of morbidity and mortality in patients with both infections. [12] [13] [14] It is estimated that 15% to 30% of patients with HIV are coinfected with HCV, and the prevalence of HCV is up to 93% in injection-drug users. 15 HIVinfected persons tend to have more severe liver disease and liver-associated mortality than HCV-infected persons without HIV disease. Two retrospective studies showed an increase in death rates form HCV reported after HAART was introduced. 16, 17 They also showed a 4-fold higher prevalence of HCV-associated cirrhosis in HIV-infected persons compared with HIV seronegatives. 18 It seems that impaired cellular immunity from HIV infection leads to accelerated HCV reproduction, with and 8-fold increase in HCV replication in HIVpositive persons compare with HIV-negatives. Conversely, HCV also accelerates the progression of HIV disease. 19 Management of coinfection with HIV and HCV should include agents against both viruses, but the timing and optimal combinations present problems related to pharmacodynamics and toxicity.
PCP
Pneumonia caused by P jiroveci (formerly classified as P carinii) was the first opportunistic infection described in AIDS. It has always been a major cause of illness and death. The term PCP has been used for decades, and rather than changing our terminology to "PJP" to reflect the new nomenclature, there is a consensus that PCP be used to refer to PCP. Once thought to be a parasite, genomic analysis revealed that P jiroveci is in fact a fungus that infects only humans, while P carinii is pathogenic only in immunodeficient rats.
Even though HAART and effective prophylaxis for PCP have existed for years, this infection still occurs for several reasons: many patients do not know that they have HIV infection until they develop an opportunistic infection, others know that they have HIV but are not receiving medical care, and some are in care and are not prescribed PCP prophylaxis or HAART. 20 Adherence to complex regimens with intolerable side effects is often problematic, and the development of resistant strains of HIV is common. Some patients take prophylaxis for PCP but are still so profoundly immunocompromised that it is ineffective. 21 Nevertheless, the incidence of PCP has declined in the era of HAART, and is reflected in the reduced rates of ICU admission for this infection. 22 The diagnosis of PCP is established by identification of the organism in specimens obtained from the respiratory tract, either in sputum induced by inhalation of hypertonic saline, or by bronchoscopy. 23 Although establishing a diagnosis is not difficult, many clinicians treat patients with suspected PCP empirically, reserving bronchoscopy for patients who do not respond to treatment. Decision-analysis modeling of these 2 strategies suggests that the outcomes are similar, but there has not been a clinical trial that has studied this question. 24 Trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred treatment of PCP in patients who have not had an adverse reaction to this drug. 25 Patients with severe PCP who do not respond or who are intolerant of this medication are usually given pentamidine, but this drug is associated with adverse reactions that are more serious than the adverse reactions associated with TMP-SMX. Trimatrexate-leucovrin is not as effective as TMP-SMX, but is better tolerated than pentamidine. 26 Whether it should replace pentamidine as a second-line treatment of moderate to severe PCP is still unresolved as comparative trials of these 2 drugs has not been performed.
When treatment of PCP is delayed or ineffective, patients develop hypoxemic respiratory failure. The clinical and radiographic features of severe PCP resemble the acute respiratory distress syndrome (ARDS), with hypoxemia, intrapulmonary shunting, reduced pulmonary compliance, and diffuse radiographic opacities ( Fig. 1 ). 27 As the disease progresses and pulmonary compliance diminishes, pneumothorax is common and is associated with a particularly poor prognosis. 28, 29 Just as severe PCP resembles ARDS clinically, the supportive treatment is similar, including intubation, mechanical ventilation, and application of positive endexpiratory pressure.
Animal models of PCP indicated that the clinical severity of infection correlates more closely with markers of inflammation than with the burden of organisms, suggesting that the immune response and its attendant inflammation account for the clinical manifestations of pneumonia. 30 Respiratory compromise is associated with the presence of activated CD8 ϩ cells and neutrophils in the lung, and corti-costeroids are thought to lessen these effects, but their mechanism of action is unclear. In patients, adjunctive corticosteroid therapy given at the start of antipneumocystis treatment reduces the likelihood of respiratory failure, deterioration of oxygenation, and death in patients with moderate to severe pneumonia. 31 Gas exchange typically deteriorates during the first few days of antipneumocystis therapy when corticosteroids are not given; 32 this is thought to be due to an inflammatory response to killed organisms. Corticosteroids may attenuate this inflammatory response to killed organisms, allowing the patient to survive to receive more antimicrobial therapy. Patients likely to benefit have a PaO 2 Ͻ70 mm Hg or an arterial-alveolar oxygen difference Ͼ35 mm Hg on room air. No benefits have been shown with less severe abnormalities in gas exchange at the start of therapy or in patients to whom corticosteroids were administered more than 72 hours after antipneumocystis treatment was begun.
Some patients with PCP are admitted to intensive care units but do not receive mechanical ventilation. The reasons for admission may include performance or complications of fiberoptic bronchoscopy, application of continuous positive airway pressure by mask, or for observation that cannot be achieved with routine floor care. These patients would be expected to have a better outcome than those who have more severe respiratory impairment, and published studies confirm that they do. 33 To counsel patients or their surrogates on whether to forgo or discontinue mechanical ventilation, it would be helpful to define predictors of "futility," where the survival rate is close to zero. For PCP, these predictors are elusive. A multicenter trial of corticosteroids for PCP showed that sur-vival after 2 weeks of mechanical ventilation was unprecedented; 34 however, the cohort only consisted of 22 of 251 patients with PCP who received mechanical ventilation, of whom 11 survived. This number is too small to support the conclusion that ventilatory support for more than 2 weeks is futile, and other centers have contradictory experience. 35 In the pre-HAART period, patients who survived mechanical ventilatory support for PCP rarely lived longer than 1 year. With the use of HAART, the prospects for long-term survival are considerably more hopeful, especially if the patient has not yet received antiretroviral therapy. 36 Therefore, while the likelihood of surviving an episode of respiratory failure due to PCP may warrant pessimism, the prospect of long-term survival with HAART should be considered in counseling patients and their surrogates on the desirability of starting or continuing mechanical ventilatory support. These decisions must always take the patient's preferences and premorbid condition into account.
Immune Reconstitution Syndromes
When HAART inhibits viral replication, there is a corresponding increase in the population of memory and naive T cells, enhancement of lymphoproliferative responses, increased IL-2 receptor expression, and reduced production of some plasma cytokines. 37 These proinflammatory effects underlie newly recognized syndromes associated with immunologic reconstitution, some involving the lung. These disorders are grouped as the "immune reconstitution inflammatory syndrome," or IRIS. In the lung, some patients develop a granulomatous disorder that resembles sarcoidosis, while others with latent or active mycobacterial infection may develop fever, lymphadenopathy, and opacities on the chest radiograph 2 to 8 weeks following immune restoration with HAART. 38, 39 IRIS may not be associated with an increase in circulating T-lymphocytes, but should be considered in any patient that has been recently started on HAART, with worsening symptoms. IRIS may be severe enough to cause respiratory failure. In one series, 3 patients developed worsening respiratory failure after HAART was introduced during treatment of PCP. 40 These patients had severe PCP and developed acute respiratory failure 7 to 17 days after starting HAART (1-16 days after being diagnosed with PCP). Their BAL and biopsy specimens showed severe immune and inflammatory reactions. The patients all improved after discontinuation of HAART, the reintroduction of corticosteroids, or both. This study raises important questions about the timing of the introduction of HAART in critically ill patients that have yet to be answered.
Toxic Effects of HAART
The protease inhibitors and nucleoside analogue reverse transcription inhibitors (NRTIs) used in HAART may carry the risk of life-threatening toxicities that prompt admis- 
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Clinical Pulmonary Medicine • Volume 12, Number 3, May 2005 sion to the ICU. Protease inhibitors may cause pancreatitis, which may be severe; in a retrospective study of 73 HIVinfected patients with pancreatitis, 46% of cases were attributed to drug toxicity. 41 Protease inhibitors also cause a syndrome of lipodystrophy, insulin resistance, and hyperlipidemia. 42 It is unknown if this syndrome will lead to excess mortality from complications of atherosclerosis, but treatment with lipid-lowering agents is problematic because of interactions with protease inhibitors. 43 Nucleoside reverse transcription inhibitors may cause lactic acidosis by disrupting mitochondrial DNA replication by selective inhibition of DNA polymerase-␥. This in turn may cause hepatic steatosis, lactic acidosis, or mitochondrial myopathy. 44, 45 Lactic acidosis is the consequence of increased anaerobic glycolysis by damaged mitochondria, coupled with decreased lactate clearance by the fatty liver. Mild hyperlactemia occurs commonly in patients receiving NRTIs and is not clinically important, but severe lactic acidosis occurs at a rate of 1.3 cases per 1000 person-years of nucleoside exposure and may be life threatening. [46] [47] [48] The initial symptoms are nausea, profuse vomiting, and abdominal pain, followed by hyperventilation, liver failure, and finally arrhythmias. Since patients may also develop severe lactic acidosis due to sepsis, empiric antibiotics are administered pending the results of a bacteriologic evaluation. If severe hyperlactemia or lactic acidosis is found, then the NRTI should be stopped immediately, and standard supportive care should be given. Case reports suggest that this disorder may improve with riboflavin, L-carnitine, and coenzyme Q. 49, 50 Abacavir is a nucleoside analog that is used in HAART regimens. It is highly potent, with good bioavailability and central nervous system penetration. However, it is also associated with hypersensitivity reactions within a few weeks of treatment in around 3% of patients, and rechallenge often leads to life-threatening anaphylaxis. 51, 52 The initial hypersensitivity reaction is characterized by fever, chill, nausea, diarrhea, and rash. The rash is not always present, sometimes misleading the clinician into diagnosing an infection. However, the anaphylactic reaction to rechallenge is diagnostic, with cardiovascular collapse and high fever. The treatment is supportive, and death is common despite these measures.
Management of Prophylaxis and HAART in Critically Ill Patients
If an HIV-infected patient develops a critical illness, prophylaxis against opportunistic pathogens like P carinii should be started or continued unless it is otherwise indicated. However, the decision to start HAART during a critical illness is problematic. Even though the use of HAART is the most important determinant of a patient's long-term survival, these drugs are often difficult to administer to critically ill patients. Only zidovudine is available in an intravenous preparation; others must be taken on schedules that take into account normal meals. All have significant interactions with other medications that may be used to treat the critical illness. For these reasons, most clinicians defer starting HAART until the acute illness has resolved or improved significantly. Patients already receiving HAART should continue to receive these drugs whenever possible, as discontinuing therapy is associated with viral replication and the emergence of resistance. In these cases, the critical care clinician is well advised to manage these patients in close collaboration with an expert in antiretroviral treatment.
Predictors of Outcome
Overall, it seems that critically ill patients with HIV infection have similar short-term outcomes as other patients with a comparable severity of illness. [53] [54] [55] However, these studies may have a selection bias as they were retrospective analyses where the admitting physicians knew the patients serostatus. A study performed in a South African surgical intensive care unit was conducted in which all patients that were admitted were tested for HIV infection without their consent. Neither the clinicians nor the patients learned the results of the HIV test unless a staff member obtained a needle-stick injury or a patient required hemodialysis. 56 On discharge, the patients were informed that they were tested and given the option of learning the test results. Posttest counseling was offered when the test results were disclosed. Fifty-two of the 402 patients (12%) admitted to the ICU had HIV infection; none had CDC-defined AIDS. None of these patients were admitted for an HIV-related disorder, and there were no differences in ICU or hospital mortality or stay when the results were adjusted for age, despite a higher incidence of sepsis and organ failure in the HIV-infected patients. It is also of interest that only 3 of the 402 patients tested wanted to know the results of their HIV test and that no patients objected to being included in the study without their consent. Despite the methodological and ethical issues this study raises (and that the authors acknowledge), it supports the concept that HIV-infected persons have similar outcomes of intensive care as uninfected patients and that decisions regarding the appropriateness of ICU interventions should not use HIV status alone as a criterion.
In attempting to predict ICU outcomes in patients with AIDS, some investigators have examined the value of laboratory tests and scoring systems, including LDH, serum albumin, CD4 ϩ lymphocyte count, APACHE II, and multisystem organ failure scores. The data are conflicting on the reliability of these prognostic variables. No measurements, including CD4 ϩ lymphocyte count, are sufficiently predictive to make firm conclusions on whether intensive care will be effective for an individual patient. 29, 57 It is clear that patients with HIV/AIDS do not have a worse short-term outcome than other patients with a similar severity of illness.
Long-term survival is related to the severity of the HIV disease or other comorbid illness. Since the outcome of intensive care does not depend directly on the patient's HIV status, serostatus and CD4 ϩ lymphocyte counts should not be overriding considerations in deciding whether to offer or withhold intensive care. Rather, these decisions should be made using the same criteria as for all patients, namely, the likelihood of benefit and the patient's wishes. In addition to the patient's illness, the experience of the hospital and health care providers in treating HIV infection and its complications also influences mortality. In one large study, adjusted mortality for patients with AIDS was 30% lower among hospitals with the most experience treating these patients. 58 Overall, the outcomes for patients with HIV infection admitted to the ICU who do not have respiratory failure is better than for those who do. 4,59 -60 
